Eton Lifts 2026 Revenue Outlook to $145M+ on 99% Q2 Surge
ETON has more than doubled off its 52-week low of $14.27.
Summary
Eton Pharmaceuticals reported Q2 2026 revenue of $37.6 million, up 99% year-over-year, and raised full-year revenue guidance to exceed $145 million. The company also lifted Adjusted EBITDA margin guidance to at least 35%.
Key Events · Earnings and Guidance · ETON
-
Q2 Revenue Up 99%
Second quarter 2026 revenue reached $37.6 million, up from $18.9 million in Q2 2025, driven by HEMANGEOL and strong portfolio growth.
-
Full-Year Guidance Raised
Management now expects 2026 revenue to exceed $145 million, up from prior guidance of more than $120 million, and Adjusted EBITDA margin of at least 35%, up from 30%.
-
ASN-001 Licensing Payment
A $3 million licensing payment for ASN-001 will be expensed in Q3 2026, impacting near-term profitability.
-
Potential ALKINDI Milestone
A one-time $4 million commercial milestone payment related to ALKINDI SPRINKLE sales may be triggered in Q4 2026.
Analysis · ETON · Life Sciences
A standout second quarter saw revenue climb 99% year-over-year to $37.6 million, swinging the company to a net profit of $11.6 million. Management responded by raising full-year revenue guidance to exceed $145 million, up from $120 million, and lifting Adjusted EBITDA margin guidance to at least 35%. The company also disclosed a $3 million licensing payment for ASN-001 and a potential $4 million milestone payment for ALKINDI SPRINKLE, both of which will affect second-half expenses. With cash of $26.8 million and a strong product portfolio, Eton is executing well, but the raised guidance and milestone payments are material new information for investors.
At the time of this filing, ETON was trading at $48.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $14.27 to $50.18. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.